QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oragenics-selects-southern-star-research-as-clinical-research-organization-for-upcoming-phase-iia-clinical-trial-of-onp-002-lead-drug-candidate-for-concussion

Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological condit...

 oragenics-enters-manufacturing-agreement-with-sterling-pharma-for-gmp-production-of-concussion-drug-onp-002

Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today ann...

 oragenics-prices-public-offering-of-up-to-20m-of-preferred-stock-and-warrants

Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurologic...

 oragenics-receives-approval-from-hrec-in-australia-to-initiate-phase-ii-clinical-trial-evaluating-onp-002-for-treatment-of-mtbi

Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorde...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION